Altius Institute For Biomedical Sciences
Altius Institute For Biomedical Sciences is a non-profit organization that provides research and analysis in the field of biomedical sciences to the federal government, focused on genetics, genomics, and aging research. Through prime federal grants from the National Institutes of Health (NIH), Altius Institute conducts research projects related to age-related gene expression and regulatory genomics. As a subawardee, Altius contributes expertise in areas such as multi-deep sequencing, phosphoproteomic profiling, and analyzing stem cells from blood donors with rare phenotypes to generate cultured red blood cells.
Specific federal grant programs Altius Institute has received funding under include research project grants from the National Institute on Aging to study causes of variegated gene expression related to aging and from the National Human Genome Research Institute to analyze principles regulating the genome. As a subawardee, Altius has provided sequencing and data analysis for genetics research led by Dana-Farber Cancer Institute and Mount Sinai, as well as supplying stem cell analysis for a project on proliferating cultured red blood cells for rare blood phenotypes led by Icahn School of Medicine.
MVEEWMEJJB24 541715
Not listed 2211 Elliott Ave Suite 200, Seattle, WA 98121, USA
11/17/15 5/14/25 Cedars-Sinai Medical Center
Cedars-Sinai Medical Center is a nonprofit hospital and academic medical center located in Los Angeles that offers specialty care from expert physicians, pioneering research, and medical education. The medical center supports federal healthcare missions by providing biomedical research, healthcare services, and preparedness efforts through prime and subcontracts and grants.
Cedars-Sinai Medical Center has provided a wide range of services through prime and subcontract awards from federal agencies like the Department of Defense, Department of Health and Human Services, Department of Veterans Affairs, and National Science Foundation. As a prime contractor, Cedars-Sinai has performed biomedical research on topics such as cancer, cardiovascular diseases, neurological disorders, and infectious diseases, often in collaboration with academic and research partners. It has also provided healthcare services, training, simulation, and preparedness efforts for agencies. Many of these prime contracts did not have set-aside designations. As a subcontractor, Cedars-Sinai has contributed specialized research services, data analysis, clinical trials support, and subject matter expertise across various biomedical and healthcare domains to prime awardees like universities and research organizations.
Through prime and subgrants, Cedars-Sinai has provided extensive biomedical research services spanning disease areas like cancer, cardiovascular, neurological, musculoskeletal, kidney, and infectious diseases. Major funders include the National Institutes of Health institutes and centers such as NCI, NHLBI, NIAID, NIDDK, and others. Key contributions involve clinical trials, genomics, biomarker discovery, drug development, disease modeling using organoids and bioengineered systems, AI/machine learning for diagnostics and prognostics, and molecular studies. As a subrecipient, Cedars-Sinai provides specialized expertise like genomic analysis, biostatistics, imaging, data management, and scientific/medical guidance to research consortia led by universities and research organizations.
Cedars-Sinai Medical Center holds a single-award indefinite delivery vehicle (IDV) contract with a potential $500 million ceiling value from the National Heart, Lung and Blood Institute. This IDV, awarded in 2023 for the Trans-Omics for Precision Medicine initiative, allows for future task orders to be placed through September 2033 for providing complex data analysis, integration and management of large-scale genomic and health datasets. The award evaluation considered responses demonstrating the ability to perform such data operations and advance precision medicine efforts for the National Institutes of Health.
NCSMA19DF7E6 622110
Not listed 8700 Beverly Blvd, West Hollywood, CA 90048, USA
12/12/00 4/2/25 Baylor College Of Medicine
Baylor College of Medicine is a private health sciences university located in Houston, Texas, that receives substantial federal funding through contracts and grants to support its biomedical research and healthcare initiatives. As a leading academic medical center, Baylor provides a wide range of services to the federal government, including conducting clinical trials, developing new medical treatments and technologies, and offering specialized medical care. The institution is particularly known for its expertise in genomics, neuroscience, cancer research, and pediatric medicine.
Through federal contracts, Baylor College of Medicine has provided expert witness services to the U.S. Attorney's Offices and gene sequencing services to the Federal Aviation Administration. The college has also been awarded contracts by the Department of Veterans Affairs to provide on-site liver and kidney transplant services at the Michael E. DeBakey VA Medical Center in Houston. These contracts have typically been awarded without set-aside designations, indicating Baylor's competitive standing in securing federal work. The institution has also served as a subcontractor on various projects, including collaborations with universities and research institutes on topics such as neural access devices and genetic sequencing for nonhuman primates.
Baylor College of Medicine's federal grant portfolio is extensive and diverse, reflecting its broad research capabilities. The institution has received numerous grants from the National Institutes of Health and its various institutes, including the National Cancer Institute, National Heart, Lung, and Blood Institute, and National Institute of Allergy and Infectious Diseases. These grants support a wide array of research projects, ranging from investigating novel cancer therapies and heart disease treatments to studying infectious diseases and rare genetic disorders. Baylor frequently collaborates with other institutions as both a prime recipient and subrecipient on these grants, working with partners such as the University of Texas MD Anderson Cancer Center, Harvard University, and various other academic and medical institutions across the country.
Baylor College of Medicine holds an indefinite delivery contract with the Department of Veterans Affairs Veterans Health Administration for on-site liver and kidney transplant services. This single-award contract, with a ceiling value of $9,030,947.90 and a performance period through March 31, 2029, allows the VA to issue delivery orders for transplant services at the Michael E. DeBakey VA Medical Center in Houston. The first delivery order under this contract, valued at $1,786,859.98, covers services from April 1, 2024, through March 31, 2025. This IDV demonstrates Baylor's ongoing commitment to providing specialized medical services to veterans and its ability to maintain long-term contractual relationships with federal agencies in the healthcare sector.
FXKMA43NTV21 611310
Not listed 1 Moursund St, Houston, TX 77030, USA
3/25/02 4/22/25 The Broad Institute, Inc.
The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, is a non-profit biomedical and genomic research organization that partners with universities, medical centers, and companies to advance understanding of human disease. Its mission is to lay the scientific foundation for the next generation of disease cures by carrying out disease area-based, cross-disciplinary research programs. Through federal contract awards from agencies like the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Department of Defense (DoD), and National Science Foundation (NSF), The Broad Institute provides an array of scientific services. These include genomic sequencing, data analysis, genome engineering, advanced computational biology, scientific software development, and translational research. The Broad collaborates with private companies, academic institutions, non-profits, and government entities as either the prime contractor or subcontractor, leveraging complementary expertise.
The Broad Institute has received numerous prime and sub federal contract awards to provide specialized scientific services. For the NIH, The Broad has conducted high-throughput whole exome sequencing on patient samples, performed genomic analyses to detect mutations and clonal architecture in cancer studies, and provided proteomics services using mass spectrometry. Under contracts with the CDC, The Broad has carried out genomic sequencing and analysis of infectious disease samples. For the DoD, The Broad has investigated mechanisms of drug resistance in cancers and developed novel antimalarial compounds. Many of these contract awards have no set-aside designation, reflecting The Broad's status as a large non-profit research organization. The Broad frequently partners with academic medical centers like Dana-Farber Cancer Institute and Massachusetts General Hospital on contract work.
The Broad Institute receives substantial grant funding from NIH institutes and centers such as the National Cancer Institute, National Institute of Mental Health, National Human Genome Research Institute, and Office of the Director. Research supported by these grants spans a wide range of areas like cancer, neuroscience, infectious disease, genomics, data science, and genome editing technology development. Broad researchers apply techniques like single-cell sequencing, spatial transcriptomics, proteomics, and metabolomics to investigate disease biology and identify therapeutic targets. The Broad frequently collaborates with partners from academia, healthcare, and industry on grant-funded projects. For example, The Broad partners with multiple universities on large-scale projects to map brain cell types and study psychiatric disorders. The institute also receives grant funding from other agencies like the DoD to advance biomedical research with potential defense applications.
The Broad Institute holds an indefinite delivery contract from the National Heart, Lung and Blood Institute to support the Trans-Omics for Precision Medicine initiative through genomics data generation, analysis, and management services. This single-award IDV has a $500 million ceiling over a 10-year period. The Broad was also awarded a multiple award IDIQ under the Brain Initiative Cell Atlas Network sequencing core program to provide large-scale DNA sequencing and related capabilities across tissue types to map cell atlases of the brain. This IDV has a $149 million ceiling shared among awardees over a 7-year period. Both of these IDCs involve task orders for work performed in Cambridge, MA by the Broad's Genomics Platform. These vehicles enable The Broad to efficiently provide genomic services to support major NIH research initiatives.
H5G9NWEFHXN4 541714
Not listed 415 Main St, Cambridge, MA 02142, USA
2/17/09 7/3/25 J. Craig Venter Institute, Inc.
J. Craig Venter Institute, Inc. (JCVI), doing business as Venter Institute Vaccines Inc., is a non-profit genomic research organization that provides a wide range of scientific services and research to the U.S. federal government through both contract and grant awards. Founded by genomics pioneer J. Craig Venter, JCVI specializes in areas such as genomics, bioinformatics, synthetic biology, and infectious disease research. The institute has received numerous awards from federal agencies including the National Institutes of Health (NIH), National Science Foundation (NSF), Department of Defense, and NASA. JCVI's work spans from basic research to applied science, with a focus on advancing human health, environmental science, and energy research through genomic discoveries and analysis.
Through federal contracts, JCVI has provided various services and research capabilities to government agencies. A notable example is a recent $5.2 million contract with the Centers for Disease Control and Prevention (CDC) for rapid plasmid synthesis and mutagenesis. The institute has also conducted research for NASA related to human adaptation to spaceflight, including studies on novel extravehicular activity architectures and the impact of diet on immune function in space. These contracts demonstrate JCVI's capabilities in molecular biology techniques and space-related biomedical research. Additionally, JCVI has engaged in smaller collaborative efforts, such as providing technical support to prime contractors like Leidos and Draper Laboratory on Department of Defense projects. It's worth noting that JCVI's contract work is not set aside for any specific business category, indicating its broad appeal and capabilities across various federal contracting needs.
JCVI's federal grant portfolio is extensive and diverse, covering a wide range of biomedical and environmental research areas. Recent grants include a $2.7 million award from the National Institute of Allergy and Infectious Diseases (NIAID) to optimize and manufacture a therapeutic bacteriophage cocktail for antibiotic-resistant Klebsiella pneumoniae infections. The institute has also received funding from NSF for projects such as developing genome transplantation techniques for non-mycoplasma bacteria and studying iron and carbon cycle coupling in marine bacteria. JCVI collaborates with numerous academic institutions as both a prime recipient and subrecipient on grants, including work on influenza virus research, coronavirus vaccine development, and cell type harmonization for single-cell genomic data. These grants showcase JCVI's expertise in genomics, synthetic biology, and bioinformatics, as well as its ability to contribute to large, multi-institutional research initiatives in fields ranging from infectious diseases to environmental microbiology.
FL8UNYTG72D1 541714
Not listed 4120 Capricorn Ln, La Jolla, CA 92037, USA
7/20/04 12/5/25